Open-label, randomized, multicentric trial across 37 sites in the United States; 134 patients were randomized to receive 125 mg of ferric gluconate versus no iron. Patients were receiving maintenance dialysis and had to have ferritin > 500 mg/dl and TSAT <25% while getting adequate doses of epoetin. Hemoglobin rose faster and higher in the intervention group, demonstrating that the supplementation of intravenous iron was capable of surpass the anemia associated to iron deficiency and inflammation.
